CATALENT, INC. (NYSE:CTLT) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
(c) New President and Chief Operating Officer
On February 13, 2019, Catalent, Inc. (the “Company”) announced that Alessandro Maselli, its Senior Vice President, Global Operations, had been appointed to the newly created position of President and Chief Operating Officer (“COO”), effective immediately. Biographical information regarding Mr. Maselli is set forth under the heading “Executive Officers” in the Company’s definitive Proxy Statement on Schedule 14A filed with the Securities and Exchange Commission (the “SEC”) on September 21, 2018 (the “Proxy Statement”), which is incorporated herein by reference.
There is no arrangement or understanding between Mr. Maselli and any other person to which he was selected as COO. There is also no family relationship between Mr. Maselli and any director or executive officer of the Company, and he has no direct or indirect material interest in any transaction required to be disclosed to Item 404(a) of Regulation S-K.
The Company amended the terms and conditions of Mr. Maselli’s employment arrangements effective February 13, 2019, raising his annual base salary by £60,000 to £385,000; raising his target bonus under the Company’s incentive-based annual cash bonus plan for its senior executives (the Management Incentive Plan, or MIP) from £206,893 to £310,000; and, effective July 1, 2019, increasing his annual target stock-incentive grant under the Company’s Long-Term Incentive Plan, or LTIP, from $450,000 to $700,000. The terms of Mr. Maselli’s existing severance agreement with the Company, which is in the standard form applicable to all senior executives other than the Company’s Chief Executive Officer and is substantially in the form provided as Exhibit 10.3 to the Annual Report on Form 10-K filed with the SEC on September 17, 2010 by the Company’s wholly owned subsidiary, Catalent Pharma Solutions, Inc., remain unchanged.
Item 7.01Regulation FD Disclosure.
A copy of the Company’s press release of February 13, 2019 announcing Mr. Maselli’s appointment has been furnished as Exhibit 99.1 to this Current Report on Form 8-K.
The information furnished to this Item 7.01, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Act of 1934, as amended, and will not be incorporated by reference into any filing under the Securities Act of 1933, as amended, unlessspecifically identified therein as being incorporated therein by reference.
Item 9.01 Financial Statements and Exhibits.
(d)Exhibits. The following exhibits are furnished as part of this Current Report on Form 8-K.
| Exhibit No. | Description |
|
99.1 |
Press Release, dated February 13, 2019, issued by Catalent, Inc. |
Catalent, Inc. Exhibit
EX-99.1 2 exhibit991pressrelease.htm EXHIBIT 99.1 DocumentExhibit 99.1Media Contacts:Chris Halling+44 (0)7580 041073chris.halling@catalent.comRichard Kerns+44 (0) 161 728 5880richard@nepr.euInvestor Relations:Thomas Castellano+1 (732) 537-6175thomas.castellano@catalent.comCatalent Names Alessandro Maselli President and Chief Operating OfficerSOMERSET,…
To view the full exhibit click here
About CATALENT, INC. (NYSE:CTLT)
Catalent, Inc. provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. Its segments include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. The Softgel Technologies segment is engaged in the formulation, development and manufacturing of prescription and consumer health soft capsules or softgels. The Drug Delivery Solutions segment is engaged in the formulation, development and manufacturing of prescription and consumer and animal health products; blow-fill seal unit dose manufacturing; biologic cell line development; analytical and bioanalytical development, and testing services. The Clinical Supply Services segment is engaged in manufacturing, packaging, labeling, storage, distribution and inventory management for clinical trials of drugs and biologics for patient kits; FastChain clinical supply service; clinical e-solutions and informatics, and global comparator sourcing services.